Dosage research on Glow Blend

Preclinical research dose ranges

In published preclinical research on the individual components, GHK-Cu in-vivo dose ranges have most commonly fallen in the 0.5 to 5 milligram per kilogram range subcutaneously for systemic endpoints, with topical applications in the 0.01 to 0.3 percent range for dermal endpoints. BPC-157 rodent dose ranges have most commonly fallen in the 1 to 10 microgram per kilogram range. TB-500 / thymosin beta-4 rodent dose ranges have most commonly fallen in the 6 to 24 milligrams per kilogram range for systemic endpoints.

No published combined-administration pharmacology study of the three components in this fixed-ratio formulation has appeared in the indexed research literature. The stacking convention combines the dermal-regeneration profile of GHK-Cu with the soft-tissue-repair profiles of BPC-157 and TB-500, with the rationale being broad-spectrum tissue-remodeling research applications rather than mechanism-specific endpoint isolation.

The Ronin catalog supplies the blend at a 50:10:10 mass ratio (GHK-Cu loading the formulation at 50 mg, BPC-157 and TB-500 each at 10 mg). The 50 mg GHK-Cu loading reflects the higher published per-dose mass conventions for GHK-Cu relative to BPC-157 and TB-500. Investigators interested in per-component contributions or precise per-component dose matching would need separate single-compound vials rather than the pre-combined Glow Blend formulation.

Dose-response considerations from the published literature

The per-component published literatures have reported dose-response characteristics described in the individual GHK-Cu, BPC-157, and TB-500 dosage research pages. No combined-administration dose-response curve for the Glow Blend formulation has appeared in the indexed published research literature.

No Phase 1 or Phase 2 dose-ranging trial of the combined three-component blend has appeared in the indexed clinical-trial literature at the time of writing. The research community continues to rely on the per-component literatures for dose-design inference.

Reconstitution math and per-vial dose calculation

A 70 mg lyophilised Glow Blend vial (50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500) reconstituted with 2 mL of bacteriostatic water yields a stock concentration of 35 mg per mL of combined formulation (25 mg per mL GHK-Cu + 5 mg per mL BPC-157 + 5 mg per mL TB-500). From this stock, a research aliquot of 0.1 mL contains 3.5 mg of combined formulation (2.5 mg GHK-Cu + 500 micrograms BPC-157 + 500 micrograms TB-500). Researchers working with the per-component dose ranges further dilute the stock to a working concentration appropriate to the model. Refrigerated storage at 2 to 8 degrees Celsius, protected from light, is the standard handling practice for all three components; the GHK-Cu component additionally requires protection from oxidising conditions to preserve the copper-bound form.

Research-protocol design considerations

Protocol-design choices in research using the Glow Blend reflect several recurring considerations. The fixed-ratio three-component formulation is the central protocol-design decision: investigators interested in per-component contributions would need separate single-compound vials. The 50:10:10 mass ratio reflects the higher published per-dose mass conventions for GHK-Cu relative to the two soft-tissue peptides.

The per-component dose-range mismatch (GHK-Cu at sub-milligram-per-kilogram subcutaneous or low-percent topical, BPC-157 at microgram-per-kilogram, TB-500 at milligram-per-kilogram systemic) is a consideration in the design rationale for the 50:10:10 mass-ratio formulation. The blend’s per-dose mass amounts are mismatched against the published per-component dose-equivalent ranges in different directions for each component.

The copper-bound GHK-Cu complexation state is a handling consideration unique among the blend’s components. Reconstituted Glow Blend should be protected from strongly oxidising conditions to preserve the copper-bound form of the GHK-Cu component; the protection requirement does not affect the BPC-157 or TB-500 components but is the binding constraint on the blend’s storage handling.

References

1. Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science Polymer Edition, 2008. [PMID 18644225]
2. Pickart L et al. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging. Oxidative Medicine and Cellular Longevity, 2012. [PMID 22666519]
3. Sikiric P et al. Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats. World Journal of Gastroenterology, 2024. [PMID 39325560]
4. Malinda KM et al. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB Journal, 1997. [PMID 9194528]
5. Sosne G et al. Thymosin beta 4 promotes corneal wound healing. Experimental Eye Research, 2002. [PMID 11950239]